Court dismisses off-label suit against Amgen
Pharma Compliance Alert, December 31, 2008
Amgen will not have to face a lawsuit from seven small health benefit plans that claimed the company improperly promoted its anemia drugs.
The U.S. District Court for the Central District of California dismissed the suit as an improper attempt to privately enforce the Food, Drug, and Cosmetic Act, according to a Reuters article. The court also ruled the plaintiffs needed to reference specific misrepresentations made by Amgen and two kidney dialysis providers.
Comments
0 comments on “Court dismisses off-label suit against Amgen ”
Related Products
Most Popular
- Articles
-
- HIPAA Q&A: Flu shot requirement for hospital employees
- Running an effective peer review committee meeting
- HealthDataInsights posts new issues for medical necessity claims
- Sneak Peek: Effort underway to establish caseload benchmarks
- Q/A: Coding for telescopic intraocular lens
- New FAQ posted on storing laryngoscope blades
- Tip: Perform your own internal investigation prior to government audit
- HIPAA 5010 deadline extended, but threat remains, says AMA
- HHS task force: Consider privacy, security with text messages
- What does case-mix index mean to you?
- E-mailed
-
- Running an effective peer review committee meeting
- HIPAA Q&A: Flu shot requirement for hospital employees
- What does case-mix index mean to you?
- HHS task force: Consider privacy, security with text messages
- Featured blog post: Nurses face felony charges after reporting physician to the Texas Medical Board
- Q/A: Coding for telescopic intraocular lens
- Q/A: Correct use of modifier -PT
- Tip: Correctly code bilateral pain management procedures
- "Wall fountains" may be spreading Legionnaires to patients, visitors
- 2012 CPT code changes for ASCs: Shoulder and knee scopes and pain management
- Searched
